Adalimumab-induced disseminated superficial porokeratosis

Annals of Pharmacotherapy

Volumn 45, Issue 2, 2011, Pages 280-281

  Guarneri, Claudio ^a   Cannavò, Serafinella P ^a   Lentini, Maria ^a   Polimeni, Giovanni ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; METHOTREXATE; PSORALEN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL RADIOGRAPHY; ADULT; CASE REPORT; DISSEMINATED SUPERFICIAL POROKERATOSIS; DRUG WITHDRAWAL; ECHOGRAPHY; FAMILY HISTORY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MALE; MEDICAL HISTORY; POROKERATOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; PSORIATIC ARTHRITIS; THORAX RADIOGRAPHY; ULTRAVIOLET RADIATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; CHEMICALLY INDUCED; MIDDLE AGED;

ADALIMUMAB; ARTHRITIS, PSORIATIC; HUMANS; MALE; MIDDLE AGED; POROKERATOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951916394     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P653     Document Type: Letter

References (5)

1. Jung JY, Yeon JH, Ryu HS, Youn SW, Park KC, Huh CH. Disseminated superficial porokeratosis developed by immunosuppression due to rheumatoid arthritis treatment. J Dermatol 2009;36:466-7.
2. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14. (Pubitemid 46349778)
3. Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998;8:459-65. (Pubitemid 28474138)
4. Stewart L, Howat A, Coulson I. Disseminated superficial porokeratosis secondary to immunosuppression induced by etanercept for extensive psoriasis. Arch Dermatol 2010;146:1193-4.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)